Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial
Open Access
- 1 October 2026
- journal article
- letter
- Published by Springer Nature in Nature Metabolism
- p. 1-12
Abstract
Cellular senescence plays an important role in hepatic inflammation and fibrosis1,2,3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (−1.43 ± 1.22 versus −0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488.Keywords
This publication has 54 references indexed in Scilit:
- Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese miceCell Metabolism, 2025
- Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical functionCell Metabolism, 2024
- Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsyHepatology International, 2023
- Hallmarks of aging: An expanding universeCell, 2023
- The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic SteatohepatitisHepatology, 2019
- Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot studyEBioMedicine, 2019
- Targeting senescent cholangiocytes and activated fibroblasts with B‐cell lymphoma‐extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/− ) miceHepatology, 2017
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Liver biopsy†Hepatology, 2009
- Chemokine Signaling via the CXCR2 Receptor Reinforces SenescenceCell, 2008